 Privately-held Cantex Pharmaceuticals Inc has entered into a licensing agreement with vTv Therapeutics Inc NASDAQ: VTVT to develop and commercialize vTvs azeliragon. Under the terms of the agreement, Cantex will be responsible for the development and commercialization of azeliragon, and the companies will allocate downstream profits under a tiered arrangement. 